Rocket Pharmaceuticals, Inc. (RCKT)
3.665
-0.12
(-3.04%)
USD |
NASDAQ |
Aug 26, 16:00
3.665
0.00 (0.00%)
After-Hours: 20:00
Rocket Pharmaceuticals Enterprise Value : 155.11M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 155.11M |
| August 24, 2026 | 127.73M |
| August 21, 2026 | 125.53M |
| August 20, 2026 | 122.25M |
| August 19, 2026 | 140.87M |
| August 18, 2026 | 106.91M |
| August 17, 2026 | 113.48M |
| August 14, 2026 | 121.15M |
| August 13, 2026 | 106.91M |
| August 12, 2026 | 114.58M |
| August 11, 2026 | 124.44M |
| August 10, 2026 | 139.77M |
| August 07, 2026 | 136.49M |
| August 06, 2026 | 128.82M |
| August 05, 2026 | 124.44M |
| August 04, 2026 | 117.87M |
| August 03, 2026 | 114.58M |
| July 31, 2026 | 81.72M |
| July 30, 2026 | 92.67M |
| July 29, 2026 | 85.00M |
| July 28, 2026 | 85.00M |
| July 27, 2026 | 97.05M |
| July 24, 2026 | 90.48M |
| July 23, 2026 | 100.34M |
| July 22, 2026 | 102.53M |
| Date | Value |
|---|---|
| July 21, 2026 | 113.48M |
| July 20, 2026 | 116.77M |
| July 17, 2026 | 117.87M |
| July 16, 2026 | 114.58M |
| July 15, 2026 | 140.87M |
| July 14, 2026 | 139.77M |
| July 13, 2026 | 148.54M |
| July 10, 2026 | 169.35M |
| July 09, 2026 | 200.02M |
| July 08, 2026 | 205.50M |
| July 07, 2026 | 186.88M |
| July 06, 2026 | 178.11M |
| July 02, 2026 | 161.68M |
| July 01, 2026 | 126.63M |
| June 30, 2026 | 115.68M |
| June 29, 2026 | 248.13M |
| June 26, 2026 | 235.04M |
| June 25, 2026 | 233.95M |
| June 24, 2026 | 240.49M |
| June 23, 2026 | 259.04M |
| June 22, 2026 | 257.95M |
| June 18, 2026 | 245.95M |
| June 17, 2026 | 225.22M |
| June 16, 2026 | 185.93M |
| June 15, 2026 | 192.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.32B |
| Oncolytics Biotech, Inc. | 103.70M |
| Sangamo Therapeutics, Inc. | 53.43M |
| Sarepta Therapeutics, Inc. | 2.256B |
| Anixa Biosciences, Inc. | 109.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 123.21M |
| Total Expenses (Quarterly) | -123.21M |
| EPS Diluted (Quarterly) | 1.076 |
| Earnings Yield | -4.91% |
| Normalized Earnings Yield | -4.917 |